Dietary Fiber May Help Reduce Colorectal Cancer Risk Linked to Gut Bacteria: Study Finds

Canada: Colorectal cancer rates have been increasing among younger individuals, prompting researchers to investigate the role of diet and gut bacteria in cancer development. A recent study by researchers at the University of Toronto explored how dietary choices interact with bacteria in the gut, particularly Escherichia coli (E. coli), to influence colorectal cancer risk.

The study was published online in Nature Microbiology on March 3, 2025, and conducted by Alberto Martin, Department of Immunology, University of Toronto, Toronto, Ontario, Canada, and colleagues.

Using a mouse model, scientists examined the effects of three different diets—low-carb, normal, and Westernized—while exposing the mice to specific bacterial strains, including Bacteroides fragilis, Helicobacter hepaticus, and colibactin-producing E. coli (pks+ E. coli). Their findings highlighted a concerning link between low-carb, low-fiber diets and increased polyp formation in the presence of pks+ E. coli, which may raise the risk of colorectal cancer.

The study revealed that mice on a low-carb, low-fiber diet colonized with pks+ E. coli developed more polyps and tumors than those on other diets. This is significant, as E. coli is found in approximately 60% of colorectal cancer cases. The low-carb diet also thinned the protective mucus layer in the colon, making it easier for colibactin, a genotoxin produced by E. coli, to damage DNA. The affected mice showed DNA damage, increased inflammation, and cellular senescence—key factors contributing to cancer development.

Interestingly, when fiber was introduced into the diet, tumor formation was reduced, and inflammation levels improved. This suggests that dietary fiber protects against the harmful effects of pks+ E. coli, possibly by maintaining gut health and reducing inflammation.

The study emphasizes the importance of diet in cancer prevention, particularly the potential dangers of low-carb diets that lack fiber. While low-carb diets, such as keto, have gained popularity for weight management, their long-term health effects remain a topic of concern. The researchers now aim to explore which types of dietary fiber offer the most protective benefits and whether similar effects are observed in humans.

These findings highlight the complex relationship between diet, gut bacteria, and cancer risk, reinforcing the importance of a balanced diet rich in fiber to support gut health and reduce the likelihood of colorectal cancer development.

“The pks+ E. coli led to more polyp growth in mice with impaired DNA repair by triggering harmful cellular changes linked to aging. Additionally, inflammation further increased its cancer-promoting effects in these mice. These findings suggest that diet and genetics play a role in how this common bacterium contributes to cancer development,” the researchers concluded.

Reference:

Thakur, B. K., Malaise, Y., Choudhury, S. R., Neustaeter, A., Turpin, W., Streutker, C., Copeland, J., Wong, E. O., Navarre, W. W., Guttman, D. S., Jobin, C., Croitoru, K., & Martin, A. (2025). Dietary fibre counters the oncogenic potential of colibactin-producing Escherichia coli in colorectal cancer. Nature Microbiology, 1-16. https://doi.org/10.1038/s41564-025-01938-4

Powered by WPeMatico

Taking semaglutide before bariatric surgery does not improve weight loss or safety, reveals research

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery, suggesting that a surgery first strategy could lead to better outcomes

A new study from Mass General Brigham could help inform conversations between providers and patients who are considering whether to try weight loss medications or surgery first. Researchers studied whether taking semaglutide, one of the new glucagon-like peptide-1 agonist (GLP-1 RAs) drugs, also known as Ozempic and Wegovy, before bariatric surgery could help patients with obesity and metabolic disease lose weight. But the retrospective study of 350 patients revealed that taking semaglutide before bariatric surgery did not improve overall weight loss or safety outcomes compared to surgery alone. The findings, published in JAMA Surgery, suggest that a surgery-first strategy may lead to better overall obesity treatment outcomes for patients.

“Many people are familiar with the new GLP-1 medicines that are available. These drugs are good options for patients to consider, and they can be used in combination with surgery,” said senior author Eric G. Sheu, MD, PhD, of the Laboratory for Surgical and Metabolic Research and chief of the Section of Bariatric and Foregut Surgery at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system. “You might expect patients to lose more weight if they take a medication prior to surgery. But we were surprised to find that the group of patients who went on medicines first and then had surgery actually had the same combined total weight loss. This contrasts with previous studies that have found that taking semaglutide after surgery can further help patients lose weight.”

Patients exploring weight-loss management strategies may elect to undergo bariatric surgery, which is the most effective and durable treatment to lose weight and reduce the risk of death from heart disease, stroke, cancer and diabetes. Previous studies have found that taking semaglutide after weight loss surgery may be effective to help lose more weight or maintain weight, although additional research is needed. The effectiveness of taking semaglutide before weight loss surgery was unknown.

Using data from the Brigham’s Center for Weight Management and Wellness, the researchers retrospectively identified 182 patients over the last seven years who were treated with semaglutide before undergoing bariatric surgery. They matched each of the patients to another patient with similar health characteristics that underwent the same type of surgery without previously taking the drugs. The study team compared the amount of weight lost, health outcomes and safety outcomes between the groups.

The researchers found that patients who took the semaglutide before surgery had a higher percentage of total weight loss at three months than patients who had weight loss surgery only. But the surgery-only group rapidly caught up, and total weight loss for the group that had received semaglutide before surgery plateaued at the same percent lost at the six-, nine-, and 12-month marks.

The researchers also found that the number and degree of safety events were similar for both groups, with no significant difference in major postoperative complications, including bleeding, leakage, infection, re-operation, re-admission or operative time. Health outcomes were also comparable between the groups, with similar levels of diabetes remission after one year.

“We are trying to figure out the best timing for these strategies to maximize their effectiveness and safety. When a patient should start the medicine, when they should stop taking it before surgery, and when they should have the surgery are things that still need to be evaluated,” said Sheu. “We also need to understand if the type of bariatric surgery matters for how patients respond to the medicines.”

Prospective studies will be an important tool for answering these questions in the future.

“We will need to conduct more research to answer the remaining questions, but there’s at least a suggestion that the most effective weight loss strategy isn’t as simple as 1 + 1 = 2,” Sheu said. “The order of strategies may be key.”

Reference:

Mathur V, Wasden K, Shin TH, et al. Neoadjuvant Semaglutide, Bariatric Surgery Weight Loss, and Overall Outcomes. JAMA Surg. Published online March 05, 2025. doi:10.1001/jamasurg.2025.0001

Powered by WPeMatico

Smoking may double Risk of Cryptogenic Ischemic Stroke, suggests research

Researchers have found in a new study that smoking doubles the risk of cryptogenic ischemic stroke (CIS). The strongest association was observed in men and individuals aged 45-49 years.

The incidence of ischemic stroke in the young is increasing and driven by cryptogenic strokes. Smoking is a well-documented risk factor with a high prevalence in young ischemic strokes. We sought to determine the association between smoking and young cryptogenic ischemic stroke (CIS) in a large multicenter case-control study. In the Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO; NCT01934725) study, patients with CIS aged 18–49 years were prospectively recruited within 2 weeks of symptom onset from 19 European stroke centers. One sex-matched and age-matched (±5 years) stroke-free control was recruited per patient. Data on tobacco use and intensity of use, socioeconomic status, and comorbidities were collected using a standardized questionnaire. Conditional logistic regression with adjustment for low education status and vascular risk factors was used to assess the association between smoking and intensity of smoking and CIS. Results: A total of 546 young patients with CIS (47.3% female) and their matched controls were included in the analysis. Univariate comparison between patients and controls showed a significant difference in low education status (55.6% vs 35.2%, p ≤ 0.001), hypertension (34.7% vs 26.8%, p ≤ 0.005), obesity (59.3% vs 44.4%, p ≤ 0.001), physical inactivity (29.4% vs 23.6%, p ≤ 0.02), smoking (32.8% vs 14.8%, p ≤ 0.001), and heavy alcohol use (13.7% vs 6.7%, p ≤ 0.001). Conditional logistic regression after adjustment showed an association between smoking and young CIS in the whole cohort with an odds ratio of 2.39 (95% CI 1.65–3.47), in men with 3.34 (1.91–5.84), and in all age groups—highest in the 45–49-year age group—with 3.77 (1.74–8.17). Analysis of smoking intensity by pack year showed the strongest association in the group with >20 pack years with an odds ratio of 4.30 (2.10–8.81), particularly in men (6.97 (2.58–18.82)) and the 45–49-year age group (4.91 (1.74–13.85)). Both smoking and high-intensity smoking were associated with CIS in the young, particularly in men and the 45–49-year age group.

Reference:

Ferdinand P, Bajpai R, Von Sarnowski B, et al. Association of Smoking and Young Cryptogenic Ischemic Stroke: A Case-Control Study. Neurology Open Access. 2025;1(1). doi:10.1212/WN9.0000000000000003.

Keywords:

Smoking, double, Risk, Cryptogenic, Ischemic, Stroke, suggests, research, Ferdinand P, Bajpai R, Von Sarnowski B

Powered by WPeMatico

Aspiring for DM Or DrNB in Neuro Anaesthesia? Know the Feeder Qualification

New Delhi: For the NEET SS 2024 aspirants seeking admission to DM/DrNB Neuro Anaesthesia, MD/DNB (Anaesthesia) has been designated as the feeder qualifications.

DM/DrNB Neuro Anaesthesia or Doctor of Medicine/Doctorate of National Board in Neuro Anaesthesia also known as DrNB in Neuro Anaesthesia is a super specialty level course for doctors in India that is done by them after completion of their postgraduate medical degree course. The duration of this super specialty course is 3 years, and it focuses on the subspecialty area of anesthesia that deals with the complex relationships of anesthetic medications, neurosurgical procedures, and the critical care issues that surround the management of these patients.

As per the information bulletin released by the National Board of Examinations (NBE), the feeder qualification for DM//DrNB Neuro Anaesthesia is MD/DNB (Anaesthesia)defined by the NBE and is subject to changes by the NBE.

The eligibility criteria for DM//DrNB Infectious Diseases are defined as the set of rules or minimum prerequisites that aspirants must meet in order to be eligible for admission, which include:

Name of course Course Type Prior Eligibility Requirement

Neuro Anaesthesia

DM/DrNB

MD/DNB (Anaesthesia)

NEET SS 2024:

ELIGIBILITY CRITERIA

The applicant must meet/fulfil the following criteria-

1 Candidates who have a recognized postgraduate medical Degree/Provisional Pass Certificate (MD/MS/DNB) or equivalent recognized qualification or are likely to have the same by 30th April 2025 by eligible feeder speciality qualifications for super speciality courses as mentioned in Annexure B of this Information Bulletin can apply for NEET-SS 2024.

2 Candidates found to be ineligible at any stage of NEET-SS 2024 will not be permitted to appear in the examination. In the unlikely event of any ineligible candidate appearing and/or being successful in NEET-SS 2024, the result/ candidature of such candidate shall be cancelled and/or is deemed to be cancelled as and when the ineligibility is detected.

3 The cutoff date for qualifying MD/MS/DNB Broad Specialty/ eligible feeder qualification towards determination of eligibility for appearing in NEET-SS 2024 shall be 30th April 2025.

4 Requests for appearing in NEET-SS 2024 from candidates who are qualifying and/or getting the results of their MD/MS/DNB qualifications/eligible feeder qualifications after 30th April 2025 shall be summarily rejected.

5 Registration with NMC/State Medical Council is mandatory and its documentary proof should be furnished at the test Centre on the examination day.

6 Foreign Nationals including Overseas Citizen of India (OCI) cardholders can appear in NEET-SS 2024 without registration with the National Medical Commission (NMC). The NMC may, on payment of the prescribed fee for registration, grant temporary registration for the duration of the post-doctoral course limited to the medical college/institution to which he/she is admitted for the time being exclusively for pursuing postdoctoral studies. Provided further that temporary registration to such foreign national shall be subject to the condition that such person is duly registered with appropriate registering authority in his/her own country where he has obtained his PG Medical qualification and is duly recognised by the corresponding Medical Council or concerned authority.

7 Candidates already pursuing or have joined a Doctoral Course (DM/MCh/DrNB) through NEET-SS are not eligible for admission to DrNB Superspecialty courses through NEET-SS 2024 for the entire duration prescribed for the course already joined by them earlier. This shall be irrespective of their resignation or discontinuation from the said course due to any reason.

8 The FCPS qualifications awarded by the College of Physicians and Surgeons, Mumbai are not equivalent to either MD or MS courses. Accordingly, candidates possessing FCPS qualifications awarded by the College of Physicians and Surgeons, Mumbai are not eligible to apply for NEET-SS, solely based on their FCPS qualifications.

9 Eligibility of candidates issued admit card for the examination shall be purely provisional. Appearing in NEET-SS 2024 does not confer any automatic rights upon the candidate for admission to DM/MCh/DrNB Super Specialty courses.

Examination Fee

Examination Fee per Group*

Rs. 3500

*Excluding charges as may be applicable by various payment gateways. GST has been EXEMPTED as per Department of Revenue, Ministry of Finance, Govt of India circular no 151/07/2021-GST dated 17.06.2021

Candidate shall be required to pay the examination fee as mentioned above for each group in which he/she chooses to appear. For eg. A candidate with MD Paediatrics qualification who chooses to appear in question papers for both Medical and Paediatric Groups shall be required to pay Rs. 3500 + 3500 = 7000/- towards examination fee. Please refer chapter on details of scheme of examination

Applications forms once submitted cannot be withdrawn. Fee shall neither be carried forward to a future date nor refunded under any circumstances. Application once submitted cannot be withdrawn. Any claim for refund, adjustment or carrying forward of Application fee will not be entertained.

How to pay: The prescribed exam fee should be remitted through payment gateway provided using a Credit Card or a Debit Card issued by banks in India or other modes as may be made available and have been provided on the web page. Fee can not be deposited through any mode other than the payment gateway available while submitting online application form submission.

Examination fees in respect of candidates who are absent or have been declared ineligible due to any reason will be forfeited. Candidates are advised to read the information bulletin for NEETSS 2024 carefully and pay examination fee only if they fulfil eligibility criteria prescribed in the bulletin.

Meanwhile, NBEMS will be conducting the NEET-SS 2024 in two slots in 2 days on a computer-based platform at various exam centres across the country. Interested candidates can start submitting the application form for the NEET-SS 2024. Below is the complete schedule-

SCHEDULE

S.NO

PROCESSES

TIMELINES

1

Online Application Submission.

4th February 2025 (3 PM Onwards) to 24th February 2025 (Till 11:55 PM).

2

Edit Window for All Applicants.

27th February 2025 to 3rd March 2025.

3

Final Edit Window to Rectify Deficient/Incorrect Images (No further opportunity shall be given)

1 Photograph.

2 Signatures.

3 Thumb Impression.

11th March 2025 to 13th March 2025.

4

Issue of Admit Card.

25th March 2025.

5

Examination Date.

29th & 30th March 2025.

6

Cut Off Date for qualifying MD/ MS/DNB Broad Specialty qualification towards determination of eligibility for appearing in NEET-SS 2024.

30th April 2025.

7

Declaration of Result.

By 30th April 2025.

Powered by WPeMatico

1471 drugs samples manufactured in HP failed quality tests in past two years: Minister

Shimla: A total of 1,471 drugs samples manufactured in Himachal Pradesh have failed quality tests over the past two years till February 25, 2025, prompting legal action against six  companies, Health and Family Welfare Minister Dhani Ram Shandil informed the Vidhan Sabha on Wednesday.

Responding to a query by Congress MLA Kewal Singh Pathania, the minister provided a district-wise breakdown of the substandard drug samples. According to the data, 33 samples were from firms based in Kangra, 302 in Sirmaur, 1,190 in Solan, and 46 in Una.

Actions such as suspension of product permissions for up to six months, issuance of show-cause notices, cancellation or surrender of licenses, and product seizures have been taken against erring pharma units, he said, adding that investigations were underway in some cases.
As per PTI report, Deputy Chief Minister Mukesh Agnihotri informed the House that 2,561 multipurpose workers were recruited in the state over the past three years till January 15, 2024, in line with departmental policies.
Responding to a question by Congress MLA Bhuvneshwar Gaur, he said that 2,502 workers were recruited in the Jal Shakti department, followed by 26 in Agriculture, 12 in Panchayati Raj, 10 in Rural Development, five in Planning, and two in Ayush.
In a reply to another question by BJP MLA Randhir Sharma, Agnihotri said the state government would procure electric buses through NABARD.
The auction process has been completed, and supply orders are being issued to the successful bidders. It is an important step towards reducing pollution, he added.
Education Minister Rohit Thakur informed the House that an expenditure of Rs 822.71 crore was incurred under the Samagra Shiksha Abhiyan in the state over the past two years.
Responding to a query by BJP MLA Sudhir Sharma, Thakur said the funds were mainly utilised for teachers’ salaries, free uniforms and books, vocational education, construction works, sports grants, and teacher training.
During 2023-24, Rs 421 crore out of the sanctioned Rs 485.97 crore was spent, while the entire sanctioned amount of Rs 336.74 crore was utilised in 2024-25, he added.

Powered by WPeMatico

Symptoms of long COVID can last up to two years after infection, research suggests

Some 23% of people infected with SARS-CoV-2 between 2021 and 2023 developed long COVID, and in more than half of them the symptoms persisted for two years. These are the main conclusions of a study conducted by ISGlobal in collaboration with the Germans Trias i Pujol Research Institute (IGTP), as part of the European END-VOC project.

Powered by WPeMatico

HIV’s latent reservoir: New insights into Nef protein offer potential strategy to improve treatment

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human immunodeficiency virus (HIV) hides dormant inside of cells shrinks when treated.

Powered by WPeMatico

Mother’s high-fat diet can cause liver stress in fetus, study shows

When mothers eat a diet high in fat and sugars, their unborn babies can develop liver stress that continues into early life. A new study published in the journal Liver International sheds light on changes to the fetus’s bile acid, which affects how liver disease develops and progresses.

Powered by WPeMatico

Synthetic breast ultrasound images: Researchers develop privacy-friendly method for medical data sharing

Medical big data holds immense potential for enhancing health care quality and advancing medical research. However, cross-center sharing of medical data, essential for constructing large and diverse datasets, raises privacy concerns and the risk of personal information misuse.

Powered by WPeMatico

Does exercise really extend life? Twin study offers new insights

Physical activity is seen as a way to extend the human lifespan, but Finnish twin studies found the benefits of physical activity for longevity may not be as straightforward as has been previously thought.

Powered by WPeMatico